Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting.
In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor.
